In 2022, the market size of ANCA Associated Vasculitis was highest in the US among the 7MM, accounting for approximately USD 620 million, which is expected to increase by 2032.

Reference Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 Update.

Emerging ANCA Vasculitis therapies in the different phases of clinical trials are- MT-2990, KYV-101, Povetacicept, NM8074, Sparsentan, Abatacept, BDB-001 injection, Avacopan, Iptacopan, ALE.F02 ...

AliveDx’s MosaiQ AiPlex Vasculitis assay now available for clinical use in EU and other CE mark accepting countries: Eysins, Switzerland Tuesday, August 5, 2025, 16:00 Hrs [IST] ...

Jayne DRW, Merkel PA, Schall TJ, Bekker P, ADVOCATE Study Group; Avacopan for the Treatment of ANCA-Associated Vasculitis; N Engl J Med. 2021 Feb 18;384 (7):599-609. doi: 10.1056/NEJMoa2023386.

As PR3-ANCA and MPO-ANCA are associated with ANCA-associated vasculitides, a positive test for ANCA by indirect immunofluorescence should be followed by PR3-specific and myeloperoxidase-specific ...

Higher scores on a measure of sinonasal symptoms can predict ANCA-associated vasculitis relapse “months to years” ahead of time, according data published in Arthritis Care & Research. The 22 ...

Bacterial DNA Motifs Trigger ANCA Production in ANCA-Associated Vasculitis in Remission Tadema H, Abdulahad WH, Lepse N, Stegeman CA, Kallenberg CG, Heeringa P Rheumatology (Oxford). 2011;50:689-696 ...

Östlund Y, Saeed A, Mihovilovic K. Patient outcomes in a Swedish single-centre cohort of ANCA-associated vasculitis with renal involvement. Presented at: ERA 2023, June 15-18, Milan, Italy.